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Recurrent pregnancy loss and thrombophilia in women with PCOSIn this issue Kazerooni and colleagues have authored an
interesting article entitled “Correlation between thrombophilia
and recurrent pregnancy loss in patients with polycystic ovary
syndrome (PCOS): A comparative study”.1 Based on the
absence or presence of recurrent pregnancy loss (RPL) and
polycystic ovary syndrome (PCOS), the authors have tried to
determine the association of thrombophilia and RPL in
patients with and without PCOS, using a case-controlled
comparative study, and separating the subjects into four
groups.1 This study attempted to shed light on two medically
challenging areas in obstetrics and gynecologydRPL and
PCOSdthe etiology of both of which is still uncertain.
RPL is defined by two or more failed pregnancies, and up
to 50% of cases of RPL will not have a clearly defined eti-
ology.2 The potential etiologic factors in the association and
causation of RPL can be separated into three categories: def-
inite, probable, and doubtful. Factors that have a definite
association with RPL include parental genetics, uterine
abnormalities, PCOS, antiphospholipid syndrome (APS), and
factor V Leiden (FVL) mutation.3 Probable associations with
RPL include uncontrolled thyroid disease, uncontrolled dia-
betes, T-helper type 1 (Th1) cell cytokine bias, increased
natural killer (NK) cell cytotoxicity, and maternal human
leukocyte antigen (HLA) levels.3 The only definite causation
of RPL has been found to be parental genetics. Other causes of
RPL include uterine abnormalities, uncontrolled thyroid dis-
ease, uncontrolled diabetes, PCOS, APS, FVL mutation, Th1
cytokine bias, increased NK cell cytotoxicity, and maternal
HLA alleles.3
One of the challenges for most researchers is how to
identify those limited RPL cases with genetic defects who are
destined to miscarry, from other treatable ones.4e6 In addition,
screening for inherited or acquired thrombophilias (especially
FVL and prothrombin gene mutations, such as prothrombin
G20210A gene mutations, and protein C, protein S, and
antithrombin deficiencies, as noted by Kazerooni et al, might
be reasonably acceptable when patients have personal history
of venous thromboembolism in a nonrecurrent risk factor
setting, or if there is a first-degree relative with a known or
suspected high-risk thrombophilia. However, any association
between hereditary thrombophilias and RPL has not been
supported by two prospective cohort studies.2,7 In addition, it
is acknowledged that APS is the only thrombophilia known to
have a direct influence on pregnancy loss, although much1726-4901/$ - see front matter Copyright  2013 Elsevier Taiwan LLC and the C
http://dx.doi.org/10.1016/j.jcma.2013.01.002research has been devoted to better ascertain the role of
thrombophilia in RPL.8
PCOS, a common endocrinopathy characterized by oligo-
or anovulation, clinical or biochemical hyperandrogenemia,
and polycystic ovaries on ultrasonography, affects 5e10% of
women of reproductive age.9,10 The search for a specific
endocrine abnormality or hematologic parameter as a pre-
dictor of pregnancy failure remains elusive.11 Extensive and
evidence-based study in this group of patients related to RPL
and thrombophilia is supposed to be more efficient and val-
uable than sporadic case reports.
In their research, Kazerooni and colleagues studied this
particular group of patients (with a combination of PCOS and
RPL), and showed an elevated level of thrombophilic param-
eters in this population.1 As predicted, this group of patients
also had higher levels of testosterone and dehydroepiandros-
trone sulfate, a higher fasting insulin level, and increased
homocysteine levels. It is interesting to find a higher preva-
lence of FVL mutations in this specific group of patients
compared to those PCOS patients without RPL. Therefore, the
authors concluded that hyperinsulinemia, hyperandrogenemia,
hypofibrinolysis, hyperhomocysteinemia, activated protein C
ratio, and FVL mutations are associated with an increased
ratio of RPL in patients with PCOS. This study supports the
previously published concept that complicated alterations in
endocrinologic, metabolic, and thrombophilic status are
associated with RPL in patients with PCOS.11e13 As for
detectable genetic disorders, Kazerooni et al’s study also
supports the fact that FVL mutation is associated with RPL in
women with PCOS.
However, Kazerooni and his colleagues failed to ultimately
provide convincing information, because they did not provide
any reliable and strict criteria to identify these patients with
genetic disorders. Consequently, the heterogeneity of the study
population and the absence of a medication history compro-
mised the value of this article, although the underlying issue
remains controversial.
In fact, extensive studies related togeneticmutations including
FVL, the methylene tetrahydrofolate reductase gene, pro-
thrombin, and the presence or absence of homozygosity in this
specific group of patients have been conducted in different
countries, with varying results and conclusions.7,12,13 A combi-
nation of multiple inherited thrombophilia mutations from both
parents rather than one specific defect of maternal origin washinese Medical Association. All rights reserved.
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come, similar to prenatal genetic consultation,4e6 which contains
many issues to be considered, including ethical, social, and
medical problems, since it is hard to make a decision only based
on these still uncertain data. To provide proper and cost-effective
preconception genetic testing or even a preimplantation embry-
onic genetic diagnosis for infertile couples with an adverse
pregnancy experience, a more detailed division of RPL into
embryonic or post-embryonic stages, first or second trimesters,
and an idiopathic or otherwise cause couldmore effectively aid in
identifying the correct and sufficient combination of genetic
defects for different categories of pregnancy loss.
In conclusion, the cause of RPL is multifactorial, and recent
guidance on the investigation and management of women with
RPL has been issued by the Royal College of Obstetricians and
Gynecologist and the American College of Obstetricians and
Gynecologists.13 These recommendations reflect the lack of an
evidence base in favor of thrombophilia testing and
anticoagulant-based intervention.13 Progressively more exten-
sive testing is being performed, which leads, on many occa-
sions, to results of questionable value. And although these
vulnerable patients often look forward to receiving any inter-
vention at all, unless they are fully informed of the evidence it
may be still difficult for them to accept “no treatment,”14
although thromboprophylaxis with aspirin or heparin com-
bined with metformin seems to be safe in pregnancy. The
supportive delicate care and the need to intervene with medi-
cation to reduce guilt and anxiety may be ultimately provided.8References
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